A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00423839|
Recruitment Status : Completed
First Posted : January 18, 2007
Last Update Posted : January 18, 2007
|Condition or disease||Intervention/treatment||Phase|
|Tuberculosis||Biological: MVA85A (Tuberculosis vaccine)||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers|
|Study Start Date :||March 2003|
|Study Completion Date :||July 2005|
- Safety of the Vaccine. This will be determined by the degree and number of adverse events reported.
- Immunogenicity of this vaccine. It is expected that the vaccine will stimulate T cell responses, which will be measured by interferon –gamma Elispot assays.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00423839
|Principal Investigator:||Helen McShane, MD and PhD||University of Oxford|